MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2022 International Congress

    USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

    AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

    Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…
  • 2022 International Congress

    Expanding the armamentarium of clinical use of apomorphine in movement disorders.

    S. Bansal, JR. Chai, M. Jog (London, Canada)

    Objective: To demonstrate the use of subcutaneous(SC) apomorphine injections in suspected untreated dopamine responsive conditions. Background: Apomorphine is a dopamine agonist historically used in dopamine…
  • MDS Virtual Congress 2021

    Apomorphine infusion before subthalamic deep brain stimulation. A prospective comparative study in the same 20 patients.

    G. Fernández-Pajarín, A. Sesar, B. Ares, I. Jimenez-Martín, M. Gelabert-González, E. Arán-Echabe, JL. Relova, A. Castro (Santiago de Compostela, Spain)

    Objective: The objetive of this study was to compare the benefit of APO and STN-DBS in aPD in terms of motor (off daily hours, UPDRS…
  • MDS Virtual Congress 2021

    Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report

    M. Auffret, V. Mathaut-Malefant, V. Denys, M. Tra, E. Boyer, V. Meuric, M. Bonnaure-Mallet, M. Vérin (Rennes, France)

    Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…
  • MDS Virtual Congress 2021

    Impact of device-aided therapies on QoL and Off-time improvement in advanced Parkinson’s Disease patients: Comparative effectiveness results from a Bayesian Network Meta-Analysis

    A. Antonini, R. Pahwa, P. Odin, S. Isaacson, A. Merola, L. Wang, P. Kandukuri, Y. Jalundhwala, A. Alobaidi, Y. Bao, C. Zadikoff, J. Parra, L. Bergmann, K. Chaudhuri (Padova, Italy)

    Objective: To compare off-time and QoL changes among APD patients taking LCIG, DBS, CSAI, and BMT at 6 months after therapy initiation. Background: Advanced Parkinson’s…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders

    A. Espay, K. Markopoulou, I. Zhang, E. Pappert, B. Navia (Cincinnati, USA)

    Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In a…
  • MDS Virtual Congress 2021

    Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease

    S. Factor, W. Ondo, S. Isaacson, I. Zhang, E. Pappert, B. Navia (Atlanta, USA)

    Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD).…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact of Concomitant Antiemetics on Nausea and Vomiting

    R. Hauser, S. Factor, W. Ondo, I. Zhang, E. Pappert, B. Navia (Tampa, USA)

    Objective: Analyze the effect of concomitant trimethobenzamide (TMB) on nausea and vomiting rates in patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia

    K. Klos, J. Hui, I. Zhang, E. Pappert, B. Navia (Tulsa, USA)

    Objective: Assess impact of apomorphine sublingual film (APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and “OFF”…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors

    A. Nicholas, C. Singer, I. Zhang, E. Pappert, B. Navia (Birmingham, USA)

    Objective: Determine if baseline factors are associated with the apomorphine sublingual film (APL) dose required to achieve FULL “ON.” Background: APL is approved for the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley